Opportunity Information: Apply for RFA HL 13 026
Apply for RFA HL 13 026
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanisms of HIV Related Lung Disease (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research.
- This funding opportunity was created on Dec 14, 2012 and posted on Dec 14, 2012.
- Applicants must submit their applications by Mar 19, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $440,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts County governments Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses State governments City or township governments Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Heart, Lung, and Blood Institute (NHLBI), within the National Institutes of Health (NIH), released the funding opportunity "Mechanisms of HIV Related Lung Disease (U01)" (Funding Opportunity Number RFA-HL-13-026) to support research that explains why and how lung diseases develop and progress in people living with HIV. The central focus is on defining the cellular and molecular mechanisms of HIV-associated lung conditions, with particular emphasis on diseases such as chronic obstructive pulmonary disease (COPD) and pulmonary hypertension. A key feature of the opportunity is its expectation that applicants will use biospecimens and well-characterized clinical data from HIV-infected individuals and appropriate control participants, allowing investigators to connect laboratory findings directly to real patient phenotypes.
This opportunity uses the NIH cooperative agreement mechanism (U01), which is designed for projects where NIH program staff anticipate substantial involvement during the conduct of the research. In practice, that means the work is not only investigator-driven but also coordinated in ways that promote consistent approaches, data sharing, and alignment across funded teams. The program is intentionally structured to include both independent, site-specific studies and collaborative research among the groups funded under the same announcement. Applicants are therefore expected to design projects that can stand on their own scientifically while also being able to integrate with a broader network, whether through shared measures, complementary assays, harmonized clinical definitions, or joint analyses.
The scientific goals are strongly translational, even though the work may be mechanistic and discovery-oriented. NHLBI encourages clinical translation to the extent feasible, such as developing or validating biomarkers that could be applied in clinical settings, or identifying molecular targets that could plausibly lead to new therapeutic strategies. The program is particularly interested in research that can identify distinct disease sub-phenotypes within HIV-associated lung disease, recognizing that conditions like COPD or pulmonary vascular disease may represent multiple biologic subtypes with different drivers and trajectories. Alongside sub-phenotyping, the announcement highlights the need for biomarkers that help predict who is at risk, how quickly disease may progress, and what outcomes are most likely, as well as mechanistic targets that could inform future interventions.
From an administrative standpoint, the opportunity was posted on December 14, 2012, with an original and final application deadline of March 19, 2013, and it was archived on April 19, 2013. The award ceiling listed for the program is $440,000. Cost sharing or matching is not required. The activity falls under the health research category and is associated with CFDA number 93.838 (Lung Diseases Research). Additional details and the full announcement were provided through the NIH Grants Guide at the listed link (http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-13-026.html).
Eligibility for this FOA was broad across U.S.-based organizations. Eligible applicants included public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations other than small businesses as well as small businesses, and a wide range of government entities (state, county, city/township, special district governments, and independent school districts). Tribal governments and tribal organizations were included (both federally recognized and other-than-federally recognized), along with public housing authorities/Indian housing authorities. The announcement also explicitly encompassed various institution types and community-based entities often referenced in NIH eligibility language, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander-serving institutions (AANAPISIs), as well as faith-based and community-based organizations and eligible federal agencies. Non-U.S. entities (foreign institutions) were not eligible to apply, and non-U.S. components of U.S. organizations were also not eligible; however, foreign components, as defined under the NIH Grants Policy Statement, were allowed, which typically enables specific, well-justified international collaborations or activities under a U.S. applicant organization.
Overall, the grant opportunity aimed to build a coordinated body of mechanistic and clinically grounded research that clarifies the biology of HIV-related lung disease, leverages patient-derived samples and data, and produces outputs that can realistically move the field toward better risk prediction, earlier detection, more precise classification of disease, and eventually more targeted treatments for pulmonary complications in people living with HIV.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "Mechanisms of HIV Related Lung Disease (U01)."
Who is offering this grant?
The funding opportunity was released by the National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health (NIH).
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-HL-13-026.
What is the main purpose of the program?
The program supports research aimed at explaining why and how lung diseases develop and progress in people living with HIV, with an emphasis on defining the cellular and molecular mechanisms that drive HIV-associated lung conditions.
Which lung diseases are specifically emphasized in this announcement?
The announcement places particular emphasis on conditions such as chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.
What type of research does NHLBI want to support here?
The focus is mechanistic and discovery-oriented research that is clinically grounded and strongly translational, meaning it should connect biological mechanisms to real patient phenotypes and, where feasible, support clinical translation (for example, biomarkers or plausible therapeutic targets).
What does "mechanisms" mean in the context of this FOA?
In this context, "mechanisms" refers to cellular and molecular processes that explain the development and progression of HIV-related lung disease, including pathways that may distinguish subtypes of disease and inform future diagnostic or therapeutic strategies.
What is the NIH activity mechanism used for this opportunity?
This opportunity uses the NIH cooperative agreement mechanism (U01).
What does a U01 cooperative agreement imply for how the project will be run?
A U01 cooperative agreement is designed for projects where NIH program staff anticipate substantial involvement during the conduct of the research. The work remains investigator-driven but is also coordinated to promote consistency, data sharing, and alignment across the funded teams.
Are applicants expected to collaborate with other funded groups?
Yes. The program is intentionally structured to include both independent, site-specific studies and collaborative research among the groups funded under the same announcement, so proposed projects should be able to stand alone scientifically and also integrate with a broader network.
How can projects be designed to integrate with the broader program network?
The announcement indicates integration may occur through shared measures, complementary assays, harmonized clinical definitions, or joint analyses across funded groups.
Is the program focused on clinical translation, or only basic science?
While the work may be mechanistic and discovery-oriented, the scientific goals are strongly translational. NHLBI encourages clinical translation where feasible, such as developing or validating biomarkers or identifying molecular targets that could plausibly lead to therapeutic strategies.
Does this FOA encourage biomarker development?
Yes. The announcement highlights the need for biomarkers that can help predict risk, rate of progression, and likely outcomes of HIV-associated lung disease.
Does this FOA encourage identifying sub-phenotypes of disease?
Yes. The program is particularly interested in identifying distinct disease sub-phenotypes within HIV-associated lung disease, recognizing that conditions like COPD or pulmonary vascular disease may include multiple biologic subtypes with different drivers and trajectories.
What is a key expectation about data and samples used in the research?
A key feature is the expectation that applicants will use biospecimens and well-characterized clinical data from HIV-infected individuals and appropriate control participants, enabling investigators to link laboratory findings directly to patient phenotypes.
Are control participants expected to be included?
Yes. The FOA specifically references using biospecimens and clinical data from HIV-infected individuals and appropriate control participants.
What kind of outputs is this program aiming to produce?
The stated aim is to build a coordinated body of mechanistic and clinically grounded research that clarifies the biology of HIV-related lung disease, leverages patient-derived samples and data, and produces outputs that can move the field toward better risk prediction, earlier detection, more precise disease classification, and eventually more targeted treatments.
What is the award ceiling for this program?
The award ceiling listed is $440,000.
Is cost sharing or matching required?
No. Cost sharing or matching is not required.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA number 93.838 (Lung Diseases Research).
What category does this activity fall under?
The activity falls under the health research category.
When was this opportunity posted?
The opportunity was posted on December 14, 2012.
What was the application deadline?
The original and final application deadline was March 19, 2013.
Is this opportunity still open for applications?
No. The opportunity was archived on April 19, 2013, and the final application deadline was March 19, 2013.
Where can applicants find the full announcement?
The full announcement was provided through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-13-026.html
Who was eligible to apply (in general terms)?
Eligibility was broad across U.S.-based organizations and included public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and many types of government entities.
Are small businesses eligible to apply?
Yes. The eligibility list includes small businesses.
Are for-profit organizations eligible to apply?
Yes. For-profit organizations (including those other than small businesses as well as small businesses) are included among eligible applicants.
Are nonprofit organizations eligible to apply?
Yes. Nonprofit organizations are eligible, including those with or without 501(c)(3) status.
Are universities and colleges eligible to apply?
Yes. Public and private institutions of higher education are listed as eligible applicants.
Which government entities are eligible to apply?
Eligible government applicants included state governments, county governments, city/township governments, special district governments, and independent school districts. Eligible federal agencies were also included.
Are tribal governments and tribal organizations eligible to apply?
Yes. The announcement includes tribal governments (federally recognized and other-than-federally recognized) and tribal organizations.
Are public housing authorities eligible to apply?
Yes. Public housing authorities/Indian housing authorities are included in the eligibility list.
Are specific institution types (such as HBCUs or Hispanic-serving institutions) included in eligibility?
Yes. The eligibility language explicitly encompasses institutions and entities such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander-serving institutions (AANAPISIs), as well as faith-based and community-based organizations.
Can foreign (non-U.S.) institutions apply directly?
No. Non-U.S. entities (foreign institutions) were not eligible to apply.
Can non-U.S. components of U.S. organizations apply or be included?
No. Non-U.S. components of U.S. organizations were also not eligible.
Are any international collaborations allowed under this FOA?
Yes. Foreign components, as defined under the NIH Grants Policy Statement, were allowed, which typically permits specific, well-justified international collaborations or activities under a U.S. applicant organization.
Browse more opportunities from the same category: Health
Next opportunity: Mechanisms of HIV Related Lung Disease Data Coordinating Center (DCC) (U01)
Previous opportunity: International Traumatic Brain Injury Research Initiative NIH Cooperative Program for Comparative Effectiveness of Clinical Tools and Therapies (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 13 026
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 13 026) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mechanisms of HIV Related Lung Disease Data Coordinating Center (DCC) (U01) Apply for RFA HL 13 028 Funding Number: RFA HL 13 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Small Research Grants for Data Analysis and Statistical Methodology Applied to Genome wide Data (R03) Apply for PAR 13 044 Funding Number: PAR 13 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening Surveillance for Japanese Encephalitis in India Apply for RFA GH 13 004 Funding Number: RFA GH 13 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| AHRQ Health Services Research Projects (R01) Apply for PA 13 045 Funding Number: PA 13 045 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| AHRQ Health Services Research Demonstration and Dissemination Grants (R18) Apply for PA 13 046 Funding Number: PA 13 046 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| Detecting etiologies of emerging infectious diseases at the regional level Western Ghat Region of Karnataka and Kerala, India Apply for RFA GH 13 003 Funding Number: RFA GH 13 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| NIH Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (P30) Apply for RFA OD 12 007 Funding Number: RFA OD 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Strengthening Disease Prevention Research Capacity for Public Health Action in Guatemala and the Central American Region Apply for RFA GH 13 001 Funding Number: RFA GH 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $20,000,000 |
| Monitoring and Evaluation of Malaria Control and Elimination Activities Apply for RFA GH 13 005 Funding Number: RFA GH 13 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Prevalence and Incidence of Inflammatory Bowel Disease Apply for RFA DP 13 001 Funding Number: RFA DP 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| NIDCD Small Grant Program (R03) Apply for PAR 13 057 Funding Number: PAR 13 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Estimating the Costs of Supporting Primary Care Practice Transformation (R03) Apply for RFA HS 13 003 Funding Number: RFA HS 13 003 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $100,000 |
| Strengthening Public Health and the Public Health Laboratory System of Cambodia under the Presidents Emergency Plan for AIDS Relief Program under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1305 Funding Number: CDC RFA GH13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| HIT Capacity Building Initiative for Ryan White HIV/AIDS Program AIDS Drug Assistance Program (ADAP) Grantees Apply for HRSA 13 152 Funding Number: HRSA 13 152 Agency: Health Resources and Services Administration Category: Health Funding Amount: $100,000 |
| R40 MCH Autism Intervention Research Apply for HRSA 13 195 Funding Number: HRSA 13 195 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| Building Systems and Capacity within the Cambodian Ministry of Health to Prevent New HIV Infections and AIDS Related Deaths in Cambodia through PEPFAR Support to the National Center for HIV/AIDS, Dermatology, and STDS (NCHADS) under the Presidents Em Apply for CDC RFA GH13 1303 Funding Number: CDC RFA GH13 1303 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Strengthening Global Animal Human Interface Activities for Avian Influenza and other Zoonotic Diseases Apply for RFA CK 13 002 Funding Number: RFA CK 13 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Epidemiology, Prevention and Treatment of Influenza and other Respiratory Infections in Panama and Central America Region Apply for RFA IP 13 002 Funding Number: RFA IP 13 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Grants to States to Support Oral Health Workforce Activities Apply for HRSA 13 142 Funding Number: HRSA 13 142 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Partnering with the Ministry of Health of Vietnam to Build a Sustainable System for HIV/AIDS Prevention, Care, and Treatment in the Socialist Republic of Vietnam under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1304 Funding Number: CDC RFA GH13 1304 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $12,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 13 026", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.